Laboratory Co. of America Holdings (NYSE:LH) Shares Sold by RMR Wealth Builders

RMR Wealth Builders lowered its position in Laboratory Co. of America Holdings (NYSE:LH) by 79.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 222 shares of the medical research company’s stock after selling 876 shares during the quarter. RMR Wealth Builders’ holdings in Laboratory Co. of America were worth $213,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Alliancebernstein L.P. lifted its position in Laboratory Co. of America by 5.3% in the fourth quarter. Alliancebernstein L.P. now owns 879,904 shares of the medical research company’s stock valued at $179,104,000 after purchasing an additional 44,288 shares during the period. Morgan Stanley increased its holdings in Laboratory Co. of America by 4.5% in the third quarter. Morgan Stanley now owns 775,591 shares of the medical research company’s stock valued at $146,021,000 after buying an additional 33,562 shares in the last quarter. Veritas Investment Management LLP increased its holdings in Laboratory Co. of America by 2.5% in the third quarter. Veritas Investment Management LLP now owns 721,105 shares of the medical research company’s stock valued at $135,759,000 after buying an additional 17,840 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Laboratory Co. of America by 11.7% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 711,952 shares of the medical research company’s stock valued at $144,918,000 after buying an additional 74,347 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in Laboratory Co. of America in the fourth quarter valued at about $101,866,000. Hedge funds and other institutional investors own 89.31% of the company’s stock.

Shares of LH opened at $243.86 on Tuesday. The firm has a market cap of $23.75 billion, a PE ratio of 28.39, a price-to-earnings-growth ratio of 1.15 and a beta of 1.09. The company’s fifty day moving average is $227.03 and its two-hundred day moving average is $202.45. Laboratory Co. of America Holdings has a fifty-two week low of $98.02 and a fifty-two week high of $252.45. The company has a quick ratio of 1.23, a current ratio of 1.36 and a debt-to-equity ratio of 0.67.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings results on Wednesday, February 10th. The medical research company reported $10.56 earnings per share for the quarter, beating the Zacks’ consensus estimate of $8.11 by $2.45. Laboratory Co. of America had a net margin of 6.79% and a return on equity of 21.05%. As a group, equities research analysts anticipate that Laboratory Co. of America Holdings will post 20.84 earnings per share for the current year.

A number of research analysts have issued reports on LH shares. JPMorgan Chase & Co. increased their target price on shares of Laboratory Co. of America from $261.00 to $279.00 and gave the company an “overweight” rating in a report on Friday, February 12th. Wolfe Research cut shares of Laboratory Co. of America from an “outperform” rating to a “peer perform” rating in a research note on Friday, January 8th. Mizuho raised their price objective on shares of Laboratory Co. of America from $242.00 to $267.00 and gave the stock a “buy” rating in a research note on Friday, February 12th. William Blair reissued an “outperform” rating on shares of Laboratory Co. of America in a research note on Tuesday, October 27th. Finally, Wells Fargo & Company raised their price objective on shares of Laboratory Co. of America from $225.00 to $260.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 28th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Laboratory Co. of America currently has a consensus rating of “Buy” and a consensus price target of $233.63.

In other Laboratory Co. of America news, CAO Peter J. Wilkinson sold 2,317 shares of Laboratory Co. of America stock in a transaction on Thursday, February 18th. The shares were sold at an average price of $241.51, for a total value of $559,578.67. Following the transaction, the chief accounting officer now owns 710 shares in the company, valued at approximately $171,472.10. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.70% of the stock is owned by company insiders.

Laboratory Co. of America Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Featured Story: How are dividend achievers different from dividend aristocrats?

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Co. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.